Latest Articles in biocon ltd
Biocon Appoints Peter Bains As Group CEO
Biocon, an Indian pharmaceutical company has appointed Peter Bains as the Group CEO, with effect from September 18th, 2023 and he will be reporting directly to Biocon Group Chairperson, Kiran Mazumdar-Shaw, the company said in a statement on Monday
Read More
Biocon Acquires Manufacturing Facility Of Eywa Pharma Inc. For $7.7 Mn
The facility is acquired for a total consideration of US USD 7.7 million. As part of the acquisition, the existing workforce of the facility will transition to Biocon Generics Inc
Read More
Biocon Tanks 4% On Account Of USFDA Observations On Malaysian Unit
The Indian biopharmaceutical company Biocon saw its stocks tumble by as high as 4.58 per cent to Rs 251.90 per scrip on Monday as of 11:04 IST on the Bombay Stock Exchange (BSE) compared to the previous close of Rs 262 on Friday
Read More
Biocon's Net Profits Soar In Q4FY23 By 31% YoY, Revenues Up By 58.6%
Bangalore-based pharmaceutical company Biocon on Tuesday announced its consolidated financial results for the fourth quarter that ended 31st March 2023, the company registered a 58.6 per cent rise in its consolidated revenues from operations year on year. The company's consolidated revenue for the M
Read More
Biocon Biologics New mAbs Facility Receives EU GMP Certification
On Friday, Biocon Biologics stated in an exchange filing that its integrated, multi-product, monoclonal antibodies (mAbs) Drug Substance manufacturing facility (B3) at Biocon Park, Bengaluru, has received a Certificate of GMP Compliance for an additional product, biosimilar Bevacizumab
Read More
Biocon Reports Net Loss Of Rs 42 Cr, Sales Up By 36% YoY In Q3FY23
Biocon's revenue for the third quarter stood at Rs 3,020 crores against Rs 2,223 crores in the same quarter last year. Whereas the company posted a net loss of Rs 42 crores in quarter three of the financial year 2023(Q3FY23
Read More
Biocon Biologics Completes Acquisition Of Viatris's Biosimilar Biz
The company said that the acquisition provides it with direct commercial capabilities and supporting infrastructure in the advanced markets and several emerging markets, bringing it closer to patients, customers, and payors
Read More